Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics (ARQT) director Howard G. Welgus sold 10,000 shares of common stock on 11/03/2025 under a Rule 10b5-1 trading plan. The weighted average sale price was $25.2669, with individual trades ranging from $25.10 to $25.4298.
Following the sale, he beneficially owned 89,744 shares, held directly. The 10b5-1 plan was adopted on March 11, 2025 and has an end date of May 29, 2026.
Arcutis Biotherapeutics (ARQT) reported an insider transaction by its SVP Chief Financial Officer. On 11/03/2025, the officer sold 88 shares of common stock at a weighted average price of $24.7185, as noted in the filing.
The footnote states the sale was made to cover tax withholding upon the vesting of Restricted Stock Units. Following the transaction, the officer beneficially owned 64,927 shares directly. The trades occurred in multiple lots between $24.435 and $25.31.
Arcutis Biotherapeutics (ARQT) reported insider activity by its President, Chief Executive Officer, and Director. On November 3, 2025, the reporting person sold 11,547 shares of common stock to cover tax withholding obligations tied to the vesting of restricted stock units.
The sales occurred at weighted-average prices of $24.7122 and $25.3991. Following these transactions, the reporting person directly owned 794,893 shares. Additional indirect holdings were reported, including 124,956 shares held by a trust and 57,358 shares held by an LLC, along with other trust-held positions.
Arcutis Biotherapeutics (ARQT) insider transaction: An officer sold shares on 11/03/2025 primarily to cover tax withholding tied to RSU vesting. The filing reports two sales: 7,165 shares at a weighted average price of $24.7123 and 43 shares at a weighted average price of $25.3985. Following these transactions, the reporting person directly held 154,026 shares. The reporting person’s title is SVP General Counsel and Corporate Secretary.
Arcutis Biotherapeutics (ARQT): President and CEO Todd Franklin Watanabe reported selling 40,000 shares of common stock on 10/28/2025 at a weighted average price of $25.0258, with individual trades ranging from $25.00 to $25.1691. The sale was made under a Rule 10b5-1 trading plan adopted on June 3, 2025, with a plan end date of September 30, 2026.
Following the transaction, he beneficially owns 806,440 shares directly. Indirect holdings include 25,410 shares by The John Franklin Watanabe Trust, 25,410 shares by The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares by Watanabe Ventures, LLC, and 124,956 shares by The Watanabe 2016 Irrevocable Trust.
Arcutis Biotherapeutics (ARQT) reported a profitable Q3 2025 driven by strong product sales. Total revenue reached $99,219,000, more than doubling from $44,755,000 a year ago, and operating income was $8,526,000. Net income was $7,410,000, a sharp turnaround from a net loss of $41,537,000 in Q3 2024. Product revenue was led by ZORYVE foam at $49,781,000, ZORYVE cream 0.3% at $30,491,000, and ZORYVE cream 0.15% at $18,947,000. Cost of sales was $8,685,000.
For the first nine months, revenue was $246,569,000 versus $125,182,000 in 2024, with a net loss of $33,536,000. Cash, cash equivalents, restricted cash, and marketable securities were $191,068,000 as of September 30, 2025. The company reported long-term debt of $100,000,000 and interest expense of $3,071,000 for the quarter. Shares outstanding were 122,492,192 as of October 22, 2025. Management notes recent approvals across multiple ZORYVE formulations in the U.S. and Canada, and recorded a $10,000,000 milestone payment to AstraZeneca tied to sales, increasing intangible assets amortized through cost of sales.
Arcutis Biotherapeutics, Inc. filed a current report to note that it issued a press release on October 28, 2025 outlining its strategy for driving sustainable growth and reporting financial results for the quarter ended September 30, 2025. The company furnished the full press release as Exhibit 99.1, rather than including detailed financial figures in the report itself. The filing clarifies that the press release is being provided for informational purposes and is not considered filed for liability purposes under the securities laws unless specifically incorporated by reference in a future filing.
Jennison Associates LLC reported beneficial ownership of 12,254,119 shares of Arcutis Biotherapeutics, Inc. common stock, representing 10.2% of the class as of the event date 09/30/2025. The filing is a Schedule 13G (Amendment No. 3), indicating passive investment reporting by an investment adviser registered in Delaware. Jennison discloses sole voting power for all 12,254,119 shares and shared dispositive power for the same amount, while claiming no sole dispositive power. The statement certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing is signed by a compliance officer on 10/06/2025.
Larry Todd Edwards, EVP Chief Commercial Officer of Arcutis Biotherapeutics (ARQT), reported sales of 4,504 shares of common stock on 10/02/2025 to cover tax withholding arising from the vesting of Restricted Stock Units granted 2/22/2024. The sales were reported as two grouped transactions: 4,207 shares at a weighted average price of $19.9885 and 297 shares at a weighted average price of $20.7801. Following the transactions, beneficial ownership is reported at 179,324 shares. The filing also notes a purchase of 724 shares under the Employee Stock Purchase Plan on 5/31/2025. The seller certified the weighted‑average price ranges and offered to provide per‑trade details on request.
Todd Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported insider sales executed under a 10b5-1 plan adopted on June 3, 2025 with a plan end date of September 30, 2026. The Form 4 discloses three sale transactions on October 1-2, 2025: 15,000 shares at a weighted average price of $18.9135, 9,261 shares at $20.0164, and 20,739 shares at $20.0383, totaling 45,000 shares sold. Following the last reported sale the Form shows 846,440 shares held directly by the reporting person. The filing notes multiple indirect holdings held in trusts and an LLC and includes undertakings to provide detailed per-trade price information on request.